P.02.22 Economic Burden of Ibd in Italy

Ruggeri, Matteo; Cicchetti, A.; Armuzzi, Alessandro; Rolli, Fr; Leone, Sierra; Previtali, Enrica

doi:10.1016/s1590-8658(18)30435-3

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observed growth of the IBDs prevalence from 2010 to 2018 in the Milan area, might pose a warning for all the other Italian areas and the Country as a whole. IBDs’ are complex [1] and costly [11,23] diseases, which affect a quite young population, with remissions and flares that may last for patients’ whole life, that is many decades. The provided Italian estimates should only be considered until a national study will provide more reliable numbers, avoiding the possible causes of overreporting (e.g.…”

Section: Discussionmentioning

confidence: 99%

“…Global Burden of Disease (GBD) estimates for 2017 account IBD prevalence in Italy as 76 581 cases [3]. However, a no-profit IBDs patients' organization, Associazione Nazionale per le Malattie Infiammatorie Croniche dell'Intestino (https://amiciitalia.eu), doubles or triples the estimate up to 150 000-200 000 prevalent cases [11]. Moreover, national projections based on recently estimated prevalence for the Tuscan region, they would indicate 500 000 the order of magnitude of the cases in our country [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy

Crocetti

Bergamaschi²,

Russo

2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Objective A reliable measure of the burden of inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, are essential to monitor their epidemiology and plan appropriate health services. Methods This is a population-based study carried out in the Milan Agency for Health Protection. Incident and prevalent cases were identified according to specific codes in hospital discharges and copayment exemptions. Age-standardized incidence rates were computed for 2015–2018 and yearly rates from 2010 to 2018, as well as annual prevalence and prevalence on 31 December 2018. Incidence and prevalence estimates for Italy were also produced. Results During 2015–2018, 3434 citizens had an IBD diagnosis, 2154 (62.7%) ulcerative colitis and 1.280 (37.3%) Crohn’s disease. Age-adjusted incidence rates were 15.3 [95% confidence interval (CI), 14.7–16.0] for ulcerative colitis and 9.4 (8.9–9.9) for Crohn’s disease. Incidence was stable during 2010–2018 for both diseases. On 31 December 2018, there were 15 141 prevalent patients, corresponding to a proportion of 442.3 every 100 000 inhabitants/year (95% CI, 435.6–449.8). Prevalence proportion has increased to around +10% per year from 2010 to 2018. Projections for Italy assessed the burden of IBD in more than 15 000 new cases/year (55% ulcerative colitis) and around 260 000 prevalent cases (62% ulcerative colitis). Conclusions The exploitation of administrative data provides reliable and up-to-date measures of the burden of disease. Incidence of IBDs is stable while prevalence notably grows. The burden of IBDs and the consequent need for care and follow-up is going to increase in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy

Crocetti

Bergamaschi²,

Russo

2021

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…Studies have suggested that the economic burden of IBD per patient on society (indirect costs) account for up to 68% of the total cost, with the annual direct cost to the patient of around €750 being dwarfed by the €2,300 cost to society per year. 6 Based on this calculation it may be speculated that the true cost of IBD is in the region of tens of billions of euros per year. On average, parents and carers of children with IBD take an additional week off from work to provide care for their child, 7 and people with IBD lose up to 20 days of recreational time every year due to their condition.…”

Section: The Problemmentioning

confidence: 98%

Making the Invisible Visible: The Hidden Cost of Paediatric Inflammatory Bowel Disease

Turner

2019

EMJ Gastroenterol

View full text Add to dashboard Cite

This year, the European Society for Gastroenterology Hepatology and Nutrition (ESPGHAN) joined forces with the European Federation of Crohn’s & Colitis Associations (EFCCA) to drive awareness of the hidden costs of paediatric inflammatory bowel diseases (IBD) and make the invisible visible. This feature puts the hidden cost of paediatric IBD in the spotlight and the author makes the case for policy makers to recognise the invisible cost of paediatric IBD. He pledges to take four key steps to reduce the burden of the diseases on society and improve the lives of children and their families.

show abstract

P.02.22 Economic Burden of Ibd in Italy

Cited by 2 publications

References 0 publications

Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy

Population-based incidence and prevalence of inflammatory bowel diseases in Milan (Northern Italy), and estimates for Italy

Making the Invisible Visible: The Hidden Cost of Paediatric Inflammatory Bowel Disease

Contact Info

Product

Resources

About